Rx0000249 |
Octapharma USA, Inc. |
12/31/2021 |
68982085003 |
Octagam 10% Vial 100Ml/10g |
10/01/2021 |
69.00 |
1796.00 |
None |
Innovator Multiple Source Drug |
None |
1 |
"Increases in US source plasma costs and manufacturing costs
resulted in the price increase for the product." |
None |
"No change or improvement to the product necessitated the price increase.
Please refer to Cost Increase Factor statement" |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=575, https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=584 |
None |
Rx0000249 |
Octapharma USA, Inc. |
12/31/2021 |
68982085004 |
Octagam 10% Vial 200Ml/20g |
10/01/2021 |
138.00 |
3592.00 |
None |
Innovator Multiple Source Drug |
None |
1 |
"Increases in US source plasma costs and manufacturing costs
resulted in the price increase for the product." |
None |
"No change or improvement to the product necessitated the price increase.
Please refer to Cost Increase Factor statement" |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=576, https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=585 |
None |
Rx0000249 |
Octapharma USA, Inc. |
12/31/2021 |
68982085001 |
Octagam 10% Vial 20Ml/2g |
10/01/2021 |
13.80 |
359.20 |
None |
Innovator Multiple Source Drug |
None |
1 |
"Increases in US source plasma costs and manufacturing costs
resulted in the price increase for the product." |
None |
"No change or improvement to the product necessitated the price increase.
Please refer to Cost Increase Factor statement" |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=573, https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=582 |
None |
Rx0000249 |
Octapharma USA, Inc. |
12/31/2021 |
68982085005 |
Octagam 10% Vial 300Ml/30g |
10/01/2021 |
207.00 |
5388.00 |
None |
Innovator Multiple Source Drug |
None |
1 |
"Increases in US source plasma costs and manufacturing costs
resulted in the price increase for the product." |
None |
"No change or improvement to the product necessitated the price increase.
Please refer to Cost Increase Factor statement" |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=577, https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=586 |
None |
Rx0000249 |
Octapharma USA, Inc. |
12/31/2021 |
68982085002 |
Octagam 10% Vial 50Ml/5g |
10/01/2021 |
34.50 |
898.00 |
None |
Innovator Multiple Source Drug |
None |
1 |
"Increases in US source plasma costs and manufacturing costs
resulted in the price increase for the product." |
None |
"No change or improvement to the product necessitated the price increase.
Please refer to Cost Increase Factor statement" |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=574, https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=583 |
None |
Rx0000249 |
Octapharma USA, Inc. |
12/31/2021 |
68982084001 |
Octagam 5% Vial /1g |
10/01/2021 |
6.90 |
179.60 |
None |
Innovator Multiple Source Drug |
None |
1 |
"Increases in US source plasma costs and manufacturing costs
resulted in the price increase for the product." |
None |
"No change or improvement to the product necessitated the price increase.
Please refer to Cost Increase Factor statement" |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=569, https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=578 |
None |
Rx0000249 |
Octapharma USA, Inc. |
12/31/2021 |
68982084003 |
Octagam 5% Vial 100Ml/5g |
10/01/2021 |
34.50 |
898.00 |
None |
Innovator Multiple Source Drug |
None |
1 |
"Increases in US source plasma costs and manufacturing costs
resulted in the price increase for the product." |
None |
"No change or improvement to the product necessitated the price increase.
Please refer to Cost Increase Factor statement" |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=571, https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=580 |
None |
Rx0000249 |
Octapharma USA, Inc. |
12/31/2021 |
68982084004 |
Octagam 5% Vial 200Ml/10g |
10/01/2021 |
69.00 |
1796.00 |
None |
Innovator Multiple Source Drug |
None |
1 |
"Increases in US source plasma costs and manufacturing costs
resulted in the price increase for the product." |
None |
"No change or improvement to the product necessitated the price increase.
Please refer to Cost Increase Factor statement" |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=572, https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=581 |
None |
Rx0000249 |
Octapharma USA, Inc. |
12/31/2021 |
68982084002 |
Octagam 5% Vial 50Ml/2.5g |
10/01/2021 |
17.25 |
449.00 |
None |
Innovator Multiple Source Drug |
None |
1 |
"Increases in US source plasma costs and manufacturing costs
resulted in the price increase for the product." |
None |
"No change or improvement to the product necessitated the price increase.
Please refer to Cost Increase Factor statement" |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=570, https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=579 |
None |
Rx0000234 |
Optinose US, Inc. |
03/31/2021 |
71143037501 |
Fluticasone Propionate (Nasal) 93 MCG/ACT Exhaler Suspension, 1 Exhaler of 16 ML |
01/01/2021 |
28.34 |
542.97 |
07/07/2035 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
Rx0000067 |
Otsuka America Pharmaceutical, Inc. |
03/31/2021 |
59148008213 |
JYNARQUE® (tolvaptan) 15 mg tablets, bottle of 30 |
01/15/2021 |
563.43 |
8612.44 |
04/07/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
JYNARQUE® is protected by an additional patent listed in FDA Orange Book with an expiration date of 9/1/2026. |
Rx0000067 |
Otsuka America Pharmaceutical, Inc. |
03/31/2021 |
59148007928 |
JYNARQUE® (tolvaptan) 15 mg/15 mg tablets, 4 x 14 weekly blister packs |
01/15/2021 |
1051.74 |
16076.56 |
04/07/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
JYNARQUE® is protected by an additional patent listed in FDA Orange Book with an expiration date of 9/1/2026. |
Rx0000067 |
Otsuka America Pharmaceutical, Inc. |
03/31/2021 |
59148008313 |
JYNARQUE® (tolvaptan) 30 mg, bottle of 30 |
01/15/2021 |
563.43 |
8612.44 |
04/07/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
JYNARQUE® is protected by an additional patent listed in FDA Orange Book with an expiration date of 9/1/2026. |
Rx0000067 |
Otsuka America Pharmaceutical, Inc. |
03/31/2021 |
59148008028 |
JYNARQUE® (tolvaptan) 30 mg/15 mg tablets, 4 x 14 weekly blister packs |
01/15/2021 |
1051.74 |
16076.56 |
04/07/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
JYNARQUE® is protected by an additional patent listed in FDA Orange Book with an expiration date of 9/1/2026. |
Rx0000067 |
Otsuka America Pharmaceutical, Inc. |
03/31/2021 |
59148008728 |
JYNARQUE® (tolvaptan) 45 mg/15 mg tablets, 4 x 14 weekly blister packs |
01/15/2021 |
1051.74 |
16076.56 |
04/07/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
JYNARQUE® is protected by an additional patent listed in FDA Orange Book with an expiration date of 9/1/2026. |
Rx0000067 |
Otsuka America Pharmaceutical, Inc. |
03/31/2021 |
59148008828 |
JYNARQUE® (tolvaptan) 60 mg/30 mg tablets, 4 x 14 weekly blister packs |
01/15/2021 |
1051.74 |
16076.56 |
04/07/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
JYNARQUE® is protected by an additional patent listed in FDA Orange Book with an expiration date of 9/1/2026. |
Rx0000067 |
Otsuka America Pharmaceutical, Inc. |
03/31/2021 |
59148008928 |
JYNARQUE® (tolvaptan) 90 mg/30 mg tablets, 4 x 14 weekly blister packs |
01/15/2021 |
1051.74 |
16076.56 |
04/07/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
JYNARQUE® is protected by an additional patent listed in FDA Orange Book with an expiration date of 9/1/2026. |
Rx0000067 |
Otsuka America Pharmaceutical, Inc. |
03/31/2021 |
59148002050 |
SAMSCA® (tolvaptan) 15 mg tablets, blister pack of 10 |
01/15/2021 |
247.71 |
5201.97 |
04/07/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
SAMSCA® is protected by an additional patent listed in FDA Orange Book with an expiration date of 9/1/2026. |
Rx0000067 |
Otsuka America Pharmaceutical, Inc. |
03/31/2021 |
59148002150 |
SAMSCA® (tolvaptan) 30 mg tablets, blister pack of 10 |
01/15/2021 |
256.97 |
5396.43 |
04/07/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
SAMSCA® is protected by an additional patent listed in FDA Orange Book with an expiration date of 9/1/2026. |
Rx0000192 |
OWP Pharmaceuticals, Inc. |
03/31/2021 |
69102013710 |
Lamotrigine USP Orange Starter Kit, (42) 25mg Tablets & (7) 100mg Tablets |
03/01/2021 |
31.00 |
648.00 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000192 |
OWP Pharmaceuticals, Inc. |
03/31/2021 |
69102030001 |
Subvenite (lamotrigine USP) Orange Starter Kit, (42) 25mg Tablets & (7) 100mg Tablets |
03/01/2021 |
31.00 |
648.00 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |